Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RESMETIROM vs REVUMENIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RESMETIROM vs REVUMENIB: Safety Overview

Metric RESMETIROM REVUMENIB
Total FAERS Reports 881 371
Deaths Reported 26 49
Death Rate 3.0% 13.2%
Hospitalizations 50 93
Average Patient Age 58.1 yrs 46.4 yrs
% Female Patients 65.3% 47.6%
FDA Approval Date Mar 14, 2024 Nov 15, 2024
Manufacturer Madrigal Pharmaceuticals, Inc. Syndax Pharmaceuticals, Inc.
Route ORAL ORAL
Marketing Status Prescription Prescription